OLISENS 0,86 mg/ml, collyre en solution en récipient unidose clinical trials

Antisense Oligonucleotide Eye Drops Against IRS-1 to Treat Pathological Corneal Neovascularisation in Aniridia-Associated Keratopathy (Olisens-Aniridia)

This study is testing new eye drops called OLISENS for people with a rare eye condition called aniridia, which can cause new blood vessels to grow on the clear front part of the eye (cornea). The drops aim to reduce these unusual blood vessels.